ABSTRACT
The dysregulated expression of kallikrein-related peptidase 6 (KLK6) is involved in non-small cancer (NSCLC) cell growth. However, the mechanism that sustains KLK6 signaling remains unknown. We used an isogenic non-small cell lung cancer (NSCLC) cell model system to demonstrate that KLK6 promotes the proliferation of lung tumoral cells and restrains their apoptosis in vitro via ligand-dependent EGFR transactivation. KLK6 activated the ERK and Akt pathways and triggered the nuclear translocation of ß-catenin. The stimulating effects of KLK6 required its proteolytic activity and were dependent on the protease-activated receptor 2 (PAR2). These observations support the concept of a role for KLK6 in the oncogenesis of NSCLC.
Subject(s)
ErbB Receptors/metabolism , Kallikreins/metabolism , Lung Neoplasms/metabolism , Lung Neoplasms/pathology , Receptor, PAR-2/metabolism , Cadherins/metabolism , Cell Line, Tumor , Cell Nucleus/metabolism , Cell Proliferation , Cell Survival , Extracellular Signal-Regulated MAP Kinases/metabolism , Gene Silencing , Humans , Ligands , Mutant Proteins/metabolism , Phosphorylation , Protein Transport , Proto-Oncogene Proteins c-akt/metabolism , beta Catenin/metabolismABSTRACT
We demonstrate the feasibility of detecting individual tumor-infiltrating cells in vivo, by means of cellular magnetic labeling and a 1.5 Tesla clinical MRI device equipped with a high-resolution surface coil. Using a recently developed high-temperature superconducting (HTS) surface coil, single cells were detected in vitro in voxels of (60 microm)(3) at magnetic loads as low as 0.2 pg of iron per cell. The same imaging protocol was used in vivo to monitor infiltration of ovalbumin-expressing tumors by transferred OVA antigen-specific cytotoxic lymphocytes with low iron load.
Subject(s)
Image Enhancement/instrumentation , Magnetic Resonance Imaging/instrumentation , Magnetic Resonance Imaging/methods , Magnetics/instrumentation , Neoplasms/pathology , Neutrophil Infiltration , T-Lymphocytes/pathology , Animals , Cell Line , Contrast Media , Equipment Design , Equipment Failure Analysis , Feasibility Studies , Ferric Compounds , Magnetics/methods , Mice , Mice, Inbred C57BLABSTRACT
OBJECTIVE: We investigated the role of monocyte-recruiting chemokines in cerebrovascular diseases among the subjects of the GENIC case-control study of brain infarction (BI). METHODS AND RESULTS: Of the genotypes tested, only homozygosity for the rare CX3CR1 alleles was more frequent in cases than in controls: the I249 and M280 alleles were associated with an increased risk of BI (OR, 1.66 and OR, 2.62 with P<0.05, respectively). This effect was independent of other established risk factors and uncorrelated with disease severity. The study confirmed previous reports of a dominant protective association between CX3CR1-I249 allele and the risk of cardiovascular history. The risk of BI associated with homozygosity for the rare CX3CR1 alleles was enhanced in patients with no previous cardiovascular events. Ex vivo studies showed that the number of monocytes adhering to immobilized CX3CL1, the CX3CR1 ligand, increased proportionally to the number of CX3CR1 mutated alleles carried by the individual. CONCLUSIONS: The rare CX3CR1 alleles were associated with an increased risk of BI and with reduced frequency of cardiovascular history. We propose that the extra adhesion of monocytes observed in individuals carrying rare alleles of CX3CR1 may favor mechanisms leading to stroke.
Subject(s)
Arteriosclerosis/epidemiology , Arteriosclerosis/genetics , Membrane Proteins/genetics , Polymorphism, Genetic , Receptors, Chemokine/genetics , Adult , Aged , Aged, 80 and over , Alleles , Arteriosclerosis/immunology , CX3C Chemokine Receptor 1 , Case-Control Studies , Cerebral Infarction/epidemiology , Cerebral Infarction/genetics , Cerebral Infarction/immunology , Female , Genetic Predisposition to Disease/epidemiology , Genotype , Humans , Male , Middle Aged , Monocytes/immunology , Myocardial Infarction/epidemiology , Myocardial Infarction/genetics , Myocardial Infarction/immunology , Risk Factors , Stroke/epidemiology , Stroke/genetics , Stroke/immunologyABSTRACT
CX3CR1 has been described previously as a marker of human cytotoxic effector cells. We evaluated the possibility of using its ligand, CX3CL1, to redirect immune response against tumors. When murine lymphoma cell lines (EL4 and its derivative EG7) stably transfected with human-CX3CL1 were injected s.c. into C57BL/6 mice, the tumor growth was severely impaired when compared with the growth of control cell lines. This antitumor effect of CX3CL1 was also found in T- and B-cell-deficient Rag1-/- mice but vanished in natural killer (NK) cell-deficient beige mice and in CX3CR1-/- mice, suggesting the involvement of CX3CR1-expressing NK cells. In addition, increased NK cell infiltration was observed in CX3CL1-producing tumors compared with controls. The effect of CX3CR1 on tumor growth required host cytotoxic effector cell functions because both IFNgamma-/- and perforin-/- mice were resistant to CX3CL1 antitumor effect. Finally, intratumoral injection of DNA plasmid coding for a chimeric immunoglobulin presenting the CX3CL1 chemokine domain provided strong antitumor activity. Together, these data demonstrate that the CX3CL1 can reduce incidence and size of lymphoma in vivo through increased recruitment of activated NK cytotoxic cells. These findings offer the first evidence of the potential of chimeric immunoglobulin-chemokines in anticancer therapy.
Subject(s)
Chemokines, CX3C/immunology , Killer Cells, Natural/immunology , Lymphoma/immunology , Membrane Proteins/immunology , Animals , B-Lymphocytes/immunology , Chemokine CX3CL1 , Chemokines, CX3C/biosynthesis , Chemokines, CX3C/genetics , DNA/administration & dosage , DNA/genetics , DNA/immunology , Female , Humans , Immunoglobulin G/genetics , Lymphoma/genetics , Lymphoma/metabolism , Membrane Proteins/biosynthesis , Membrane Proteins/genetics , Mice , Mice, Inbred C57BL , Mice, Nude , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/immunology , T-Lymphocytes/immunology , TransfectionABSTRACT
Hepatocellular carcinoma (HCC) is the 3rd cause of cancer-related death worldwide. Most cases arise in a background of chronic inflammation, extracellular matrix (ECM) remodeling, severe fibrosis and stem/progenitor cell amplification. Although HCCs are soft cellular tumors, they may contain fibrous nests within the tumor mass. Thus, the aim of this study was to explore cancer cell phenotypes in fibrous nests. Combined anatomic pathology, tissue microarray and real-time PCR analyses revealed that HCCs (n=82) containing fibrous nests were poorly differentiated, expressed Wnt pathway components and target genes, as well as markers of stem/progenitor cells, such as CD44, LGR5 and SOX9. Consistently, in severe liver fibroses (n=66) and in HCCs containing fibrous nests, weighted correlation analysis revealed a gene network including the myofibroblast marker ACTA2, the basement membrane components COL4A1 and LAMC1, the Wnt pathway members FZD1; FZD7; WNT2; LEF1; DKK1 and the Secreted Frizzled Related Proteins (SFRPs) 1; 2 and 5. Moreover, unbiased random survival forest analysis of a transcriptomic dataset of 247 HCC patients revealed high DKK1, COL4A1, SFRP1 and LAMC1 to be associated with advanced tumor staging as well as with bad overall and disease-free survival. In vitro, these genes were upregulated in liver cancer stem/progenitor cells upon Wnt-induced mesenchymal commitment and myofibroblast differentiation. In conclusion, fibrous nests express Wnt target genes, as well as markers of cancer stem cells and mesenchymal commitment. Fibrous nests embody the specific microenvironment of the cancer stem cell niche and can be detected by routine anatomic pathology analyses.
Subject(s)
Carcinoma, Hepatocellular/genetics , Carcinoma, Hepatocellular/pathology , Gene Expression Regulation, Neoplastic , Liver Neoplasms/genetics , Liver Neoplasms/pathology , Wnt Proteins/metabolism , Actins/metabolism , Basement Membrane/metabolism , Biomarkers, Tumor/metabolism , Carcinoma, Hepatocellular/complications , Carcinoma, Hepatocellular/diagnosis , Cell Differentiation , Humans , Laminin/metabolism , Liver Cirrhosis/complications , Liver Neoplasms/complications , Liver Neoplasms/diagnosis , Mesoderm/pathology , Myofibroblasts/pathology , Neoplasm Invasiveness , Neoplastic Stem Cells/pathology , Prognosis , Recurrence , Tumor Microenvironment , Wnt Signaling Pathway/geneticsABSTRACT
About 20% hepatocellular carcinomas (HCCs) display wild-type ß-catenin, enhanced Wnt signaling, hepatocyte dedifferentiation and bad outcome, suggesting a specific impact of Wnt signals on HCC stem/progenitor cells. To study Wnt-specific molecular pathways, cell fates and clinical outcome, we fine-tuned Wnt/ß-catenin signaling in liver progenitor cells, using the prototypical Wnt ligand Wnt3a. Cell biology assays and transcriptomic profiling were performed in HepaRG hepatic progenitors exposed to Wnt3a after ß-catenin knockdown or Wnt inhibition with FZD8_CRD. Gene expression network, molecular pathology and survival analyses were performed on HCCs and matching non-tumor livers from 70 patients by real-time PCR and tissue micro-array-based immunohistochemistry. Wnt3a reprogrammed liver progenitors to replicating fibrogenic myofibroblast-like cells displaying stem and invasive features. Invasion was inhibited by 30 nM FZD7 and FZD8 CRDs. Translation of these data to human HCCs revealed two tight gene networks associating cell surface Wnt signaling, stem/progenitor markers and mesenchymal commitment. Both networks were linked by Hyaluronan And Proteoglycan Link Protein 1 (HAPLN1), that appeared de novo in aggressive HCCs expressing cytoplasmic ß-catenin and stem cell markers. HAPLN1 was independently associated with bad overall and disease-free outcome. In vitro, HAPLN1 was expressed de novo in EPCAM¯/NCAM+ mesoderm-committed progenitors, upon spontaneous epithelial-mesenchymal transition and de-differentiation of hepatocyte-like cells to liver progenitors. In these cells, HAPLN1 knockdown downregulated key markers of mesenchymal cells, such as Snail, LGR5, collagen IV and α-SMA. In conclusion, HAPLN1 reflects a signaling network leading to stemness, mesenchymal commitment and HCC progression.
Subject(s)
Carcinoma, Hepatocellular/metabolism , Extracellular Matrix Proteins/metabolism , Gene Expression Regulation, Neoplastic , Liver Neoplasms/metabolism , Mesoderm/metabolism , Proteoglycans/metabolism , Stem Cells/metabolism , Wnt Proteins/metabolism , Aged , Cell Differentiation , Cell Line , Cell Line, Tumor , Cluster Analysis , Extracellular Matrix Proteins/genetics , Female , Fibroblasts/metabolism , Follow-Up Studies , Gene Expression Profiling , Humans , Immunohistochemistry , Ligands , Liver/metabolism , Liver/pathology , Male , Middle Aged , Neoplasm Invasiveness , Proteoglycans/genetics , Signal Transduction , Stem Cells/cytology , Tissue Array AnalysisABSTRACT
The Wnt/ß-catenin pathway controls cell proliferation, death and differentiation. Several families of extracellular proteins can antagonize Wnt/ß-catenin signaling, including the decoy receptors known as secreted frizzled related proteins (SFRPs), which have a cysteine-rich domain (CRD) structurally similar to the extracellular Wnt-binding domain of the frizzled receptors. SFRPs inhibit Wnt signaling by sequestering Wnts through the CRD or by forming inactive complexes with the frizzled receptors. Other endogenous molecules carrying frizzled CRDs inhibit Wnt signaling, such as V3Nter, which is proteolytically derived from the cell surface component collagen XVIII and contains a biologically active frizzled domain (FZC18) inhibiting in vivo cell proliferation and tumor growth in mice. We recently showed that FZC18 expressing cells deliver short-range signals to neighboring cells, decreasing their proliferation in vitro and in vivo through the Wnt/ß-catenin signaling pathway. Here, using low concentrations of soluble FZC18 and Wnt3a, we show that they physically interact in a cell-free system. In addition, soluble FZC18 binds the frizzled 1 and 8 receptors' CRDs, reducing cell sensitivity to Wnt3a. Conversely, inhibition of Wnt/ß-catenin signaling was partially rescued by the expression of full-length frizzled 1 and 8 receptors, but enhanced by the expression of a chimeric cell-membrane-tethered frizzled 8 CRD. Moreover, soluble, partially purified recombinant FZC18_CRD inhibited Wnt3a-induced ß-catenin activation. Taken together, the data indicate that collagen XVIII-derived frizzled CRD shifts Wnt sensitivity of normal cells to a lower pitch and controls their growth.
Subject(s)
Collagen Type XVIII/chemistry , Collagen Type XVIII/metabolism , Collagen Type XVIII/pharmacology , Frizzled Receptors/metabolism , Wnt Signaling Pathway/drug effects , Wnt3 Protein/metabolism , Animals , Cell Proliferation/drug effects , DNA/biosynthesis , Extracellular Space/drug effects , Extracellular Space/metabolism , HEK293 Cells , Humans , Mice , Models, Biological , Protein Binding/drug effects , Protein Multimerization/drug effects , Protein Structure, Tertiary , Solubility/drug effectsABSTRACT
Collagens contain cryptic polypeptide modules that regulate major cell functions, such as cell proliferation or death. Collagen XVIII (C18) exists as three amino terminal end variants with specific amino terminal polypeptide modules. We investigated the function of the variant 3 of C18 (V3C18) containing a frizzled module (FZC18), which carries structural identity with the extracellular cysteine-rich domain of the frizzled receptors. We show that V3C18 is a cell surface heparan sulfate proteoglycan, its topology being mediated by the FZC18 module. V3C18 mRNA was expressed at low levels in 21 normal adult human tissues. Its expression was up-regulated in fibrogenesis and in small well-differentiated liver tumors, but decreased in advanced human liver cancers. Low FZC18 immunostaining in liver cancer nodules correlated with markers of high Wnt/beta-catenin activity. V3C18 (M(r) = 170 kD) was proteolytically processed into a cell surface FZC18-containing 50 kD glycoprotein precursor that bound Wnt3a in vitro through FZC18 and suppressed Wnt3a-induced stabilization of beta-catenin. Ectopic expression of either FZC18 (35 kD) or its 50 kD precursor inhibited Wnt/beta-catenin signaling in colorectal and liver cancer cell lines, thus downregulating major cell cycle checkpoint gatekeepers cyclin D1 and c-myc and reducing tumor cell growth. By contrast, full-length V3C18 was unable to inhibit Wnt signaling. In summary, we identified a cell-surface signaling pathway whereby FZC18 inhibits Wnt/beta-catenin signaling. The signal, encrypted within cell-surface C18, is released by enzymatic processing as an active frizzled cysteine-rich domain (CRD) that reduces cancer cell growth. Thus, extracellular matrix controls Wnt signaling through a collagen-embedded CRD behaving as a cell-surface sensor of proteolysis, conveying feedback cues to control cancer cell fate.
Subject(s)
Collagen/physiology , Frizzled Receptors/metabolism , Signal Transduction , Wnt Proteins/metabolism , beta Catenin/metabolism , Cell Line, Tumor , Cell Lineage , Cell Membrane/metabolism , Collagen/chemistry , Extracellular Matrix/metabolism , Gene Expression Regulation, Neoplastic , Humans , Liver Neoplasms/metabolism , Models, Biological , Protein Processing, Post-Translational , Protein Structure, TertiaryABSTRACT
Chemokines and their receptors are key regulators of inflammation and may participate in the lung fibrotic process. Associations of polymorphisms in CCL5 (G-403A) and its receptor CCR5 (Delta32), CCL2 (A-2578G) and CCR2 (V64I), and CX3CR1 V249I and T280M with coal worker's pneumoconiosis (CWP) were investigated in 209 miners examined in 1990, 1994 and 1999. Coal dust exposure was assessed by job history and ambient measures. The main health outcome was lung computed tomography (CT) score in 1990. Internal coherence was assessed by studying CT score in 1994, 4-year change in CT score, and CWP prevalence in 1999. CCR5 Delta32 carriers had significantly higher CT score in 1990 and 1994 (2.15 vs. 1.28, p=0.01; 3.04 vs. 1.80, p=0.04). The CX3CR1 I249 allele was significantly associated with lower 1990 CT score and lower progression in 4-year change in CT score in CCR5 Delta32 carriers only (p for interaction=0.03 and 0.02). CX3CR1 V249I was associated with lower 1999 CWP prevalence (16.7%, 13.2%, 0.0% for VV, VI and II); the effect was most evident in miners with high dust exposure (31.6%, 21.7%, 0.0%). Our findings indicate that chemokine receptors CCR5 and CX3CR1 may be involved in the development of pneumoconiosis.
Subject(s)
Chemokines/genetics , Coal Mining , Pneumoconiosis/genetics , Polymorphism, Genetic , Receptors, Chemokine/genetics , Adult , CX3C Chemokine Receptor 1 , Chemokine CCL2/genetics , Chemokine CCL5 , Chemokines, CC/genetics , Gene Frequency , Genotype , Humans , Membrane Proteins/genetics , Middle Aged , Phenotype , Pneumoconiosis/diagnosis , Pneumoconiosis/epidemiology , Polymorphism, Single Nucleotide , Prevalence , Receptors, CCR2 , Receptors, CCR5/geneticsABSTRACT
The aim of this study was to demonstrate the feasibility of in vivo cell tracking to monitor anticancer cell therapy by means of a high-resolution noninvasive MRI method. Ovalbumin-specific splenocytes (OT-1) labeled with anionic gamma-Fe2O3 superparamagnetic iron oxide (SPIO) nanoparticles were adoptively transferred into C57BL/6 mice with growing ovalbumin-expressing tumors. OT-1 cells were tracked in vivo by 7 T MRI 24, 48, and 72 hr after they were injected. The results showed significant negative enhancement of the spleen at 24 hr, and of the tumor at 48 and 72 hr, after labeled cell injection. This suggests that the lymphocytes initially homed toward the spleen and were then recruited by the tumor. The presence of labeled cells was confirmed in ex vivo by 9.4 T microimaging of tumors and magnetic sorting of spleen cells. These results confirm that MR tracking of lymphocytes is feasible in vivo. This high-resolution imaging method could be used to improve the monitoring of immune cell therapy.
Subject(s)
Image Enhancement/methods , Image Interpretation, Computer-Assisted/methods , Immunotherapy, Adoptive/methods , Lymphocyte Transfusion/methods , Lymphocytes/pathology , Lymphoma/pathology , Magnetic Resonance Imaging/methods , Animals , Cell Line, Tumor , Contrast Media , Feasibility Studies , Female , Lymphocytes/immunology , Lymphoma/immunology , Lymphoma/therapy , Mice , Mice, Inbred C57BLABSTRACT
Understanding both the role of tumor Ag in CD8 cell differentiation and the reasons that CD8 cells may work inefficiently is crucial for therapeutic approaches in cancer. We studied OT-1 CD8 cell responses in vivo in a differential Ag-distribution model that used EG-7, the EL-4 thymoma transfected with OVA. On their initial Ag encounter, OT-1 CD8 cells underwent programmed expansion in the lymph nodes, where they acquired the ability to migrate to the encapsulated tumor site after > or =4 divisions, without continuous antigenic stimulation. This short antigenic stimulation was sufficient to induce the migration differentiation program, which included modulation of chemokine receptor mRNA expression and down-regulation of CD62L. Moreover, Ag quantity determined the behavior of the OT-1 CD8 cells, including their effector functions and sensitivity to apoptosis. Thus, the initial Ag encounter drives the programmed cell migration potencies, but neither effector functions nor cell death can occur without continuous TCR triggering.
Subject(s)
Antigens, Neoplasm/analysis , CD8-Positive T-Lymphocytes/immunology , Neoplasms, Experimental/immunology , Animals , CD8-Positive T-Lymphocytes/physiology , Cell Differentiation , Cell Line, Tumor , Cell Movement , Cytotoxicity, Immunologic , Female , Interferon-gamma/biosynthesis , Lymphocyte Activation , Mice , Neoplasms, Experimental/therapy , Ovalbumin/immunology , Receptors, Antigen, T-Cell/physiology , Receptors, Chemokine/analysisABSTRACT
Chemokines participate in the antitumor immune response by regulating the movement and positioning of lymphocytes as well as effector functions and may thus be candidates for use in antitumor therapy. To test whether CCL5, a chemokine involved in the recruitment of a wide spectrum of immunocompetent cells, can control tumor growth, we forced its expression at mouse tumor sites. Tumor growth was reduced in mice with s.c. syngeneic CCL5-EL-4 compared with EL-4-injected mice, whereas both reduced tumor growth and incidence were observed in mice with OVA-expressing EG-7 transfected with CCL5 compared with EG-7-injected mice. Significant antitumor effects were observed soon after intratumoral injection of DNA plasmid coding for chimeric CCL5-Ig. Importantly, quantitative RT-PCR assays showed that the amount of CCL5 expression at the tumor site determined the effectiveness of the antitumor response, which was associated with infiltration of increased numbers of NK, CD4, and CD8 cells at the tumor site. This effect was lost in mice deficient for T/B lymphocytes (RAG-2 knockout) or for CCR5 (CCR5 knockout). Together, these data demonstrate the antitumor activity of intratumoral CCL5 overexpression, due to its recruitment of immunocompetent cells, and the potential usefulness of chimeric CCL5-Ig DNA as an agent in cancer therapy.
Subject(s)
Chemokines, CC/biosynthesis , Chemokines, CC/physiology , Chemotaxis, Leukocyte/immunology , Growth Inhibitors/biosynthesis , Growth Inhibitors/genetics , Lymphoma/pathology , Lymphoma/prevention & control , Animals , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/pathology , CD8-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/pathology , Cell Division/genetics , Cell Division/immunology , Cell Line, Tumor , Chemokine CCL5 , Chemokines, CC/deficiency , Chemokines, CC/genetics , Chemotaxis, Leukocyte/genetics , DNA-Binding Proteins/deficiency , DNA-Binding Proteins/genetics , Dendritic Cells/immunology , Dendritic Cells/pathology , Growth Inhibitors/deficiency , Growth Inhibitors/physiology , Immunotherapy, Adoptive/methods , Injections, Intralesional , Killer Cells, Natural/immunology , Killer Cells, Natural/pathology , Lymphoma/genetics , Lymphoma/immunology , Mice , Mice, Inbred C57BL , Mice, Knockout , Neoplasm Transplantation/immunology , Recombinant Fusion Proteins/administration & dosage , Recombinant Fusion Proteins/physiology , Recombinant Fusion Proteins/therapeutic use , Vaccines, DNA/administration & dosage , Vaccines, DNA/genetics , Vaccines, DNA/immunologyABSTRACT
It was recently shown that individuals carrying the naturally occurring mutant CX3CR1-Ile(249)-Met(280) (hereafter called CX3CR1-IM) have a lower risk of cardiovascular disease than individuals homozygous for the wild-type CX3CR1-Val(249)-Thr(280) (CX3CR1-VT). We report here that peripheral blood mononuclear cells (PBMC) from individuals with the CX3CR1-IM haplotype adhered more potently to membrane-bound CX3CL1 than did PBMC from homozygous CX3CR1-VT donors. Similar excess adhesion was observed with CX3CR1-IM-transfected human embryonic kidney (HEK) cell lines tested with two different methods: the parallel plate laminar flow chamber and the dual pipette aspiration technique. Suppression of the extra adhesion in the presence of pertussis toxin indicates that G-protein mediated the underlying transduction pathway, in contrast to the G-protein-independent adhesion previously described for CX3CR1-VT. Surprisingly, HEK and PBMC that expressed CX3CR1-IM and -VT were indistinguishable when tested with the soluble form of CX3CL1 for chemotaxis, calcium release, and binding capacity. In conclusion, only the membrane-anchored form of CX3CL1 functionally discriminated between these two allelic isoforms of CX3CR1. These results suggest that each form of this ligand may lead to a different signaling pathway. The extra adhesion of CX3CR1-IM may be related to immune defenses and to atherogenesis, both of which depend substantially on adhesive intercellular events.